Teva Pharmaceutical Industries LTD TEVA
We take great care to ensure that the data presented and summarized in this overview for TEVA PHARMACEUTICAL INDUSTRIES LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TEVA
View all-
Black Rock Inc. New York, NY43MShares$1.09 Billion0.02% of portfolio
-
Phoenix Holdings Ltd. Givatayim, L341.3MShares$1.05 Billion10.51% of portfolio
-
Menora Mivtachim Holdings Ltd.38.9MShares$989 Million4.08% of portfolio
-
Harel Insurance Investments & Financial Services Ltd.37.7MShares$958 Million6.84% of portfolio
-
Migdal Insurance & Financial Holdings Ltd.32.6MShares$828 Million7.09% of portfolio
-
Clal Insurance Enterprises Holdings LTD Tel Aviv, L331.5MShares$800 Million4.83% of portfolio
-
Exor Capital LLP London, X028.6MShares$726 Million14.21% of portfolio
-
Rubric Capital Management LP New York, NY24.7MShares$626 Million8.19% of portfolio
-
Point State Capital LP New York, NY20.7MShares$526 Million7.71% of portfolio
-
State Street Corp Boston, MA17.2MShares$436 Million0.01% of portfolio
Latest Institutional Activity in TEVA
Top Purchases
Top Sells
About TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Insider Transactions at TEVA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2025
|
Mark Sabag |
SELL
Open market or private sale
|
Direct |
216,892
-54.52%
|
$6,072,976
$28.73 P/Share
|
|
Dec 09
2025
|
Mark Sabag |
BUY
Exercise of conversion of derivative security
|
Direct |
118,724
+30.56%
|
$2,137,032
$18.61 P/Share
|
|
Dec 09
2025
|
Richard Daniell Exec. VP, European Commercial |
SELL
Open market or private sale
|
Direct |
115,468
-70.47%
|
$3,233,104
$28.68 P/Share
|
|
Dec 09
2025
|
Richard Daniell Exec. VP, European Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
115,468
+24.34%
|
$1,962,956
$17.8 P/Share
|
|
Dec 02
2025
|
Chen Lichtenstein |
BUY
Exercise of conversion of derivative security
|
Direct |
4,804
+50.0%
|
-
|
|
Nov 26
2025
|
Roberto Mignone |
SELL
Open market or private sale
|
Indirect |
50,000
-10.1%
|
$1,300,000
$26.03 P/Share
|
|
Nov 20
2025
|
Christine Fox EVP, Head of U.S. Commercial |
SELL
Open market or private sale
|
Direct |
28,229
-30.73%
|
$677,496
$24.78 P/Share
|
|
Nov 20
2025
|
Christine Fox EVP, Head of U.S. Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
63,492
+40.87%
|
-
|
|
Nov 14
2025
|
Christine Fox EVP, Head of U.S. Commercial |
SELL
Open market or private sale
|
Direct |
30,000
-51.38%
|
$750,000
$25.11 P/Share
|
|
Nov 06
2025
|
Roberto Mignone |
SELL
Open market or private sale
|
Indirect |
200,000
-28.78%
|
$4,800,000
$24.11 P/Share
|
|
Nov 06
2025
|
Amir Weiss Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,300
-40.66%
|
$295,200
$24.44 P/Share
|
|
Sep 05
2025
|
David R. Mc Avoy EVP, Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
1,113
+7.87%
|
$20,034
$18.86 P/Share
|
|
Aug 01
2025
|
Placid Jover |
SELL
Open market or private sale
|
Direct |
6,053
-47.19%
|
$90,795
$15.16 P/Share
|
|
Aug 01
2025
|
Placid Jover |
BUY
Exercise of conversion of derivative security
|
Direct |
12,827
+50.0%
|
-
|
|
Aug 01
2025
|
Eric A Hughes |
SELL
Open market or private sale
|
Direct |
52,742
-100.0%
|
$791,130
$15.16 P/Share
|
|
Aug 01
2025
|
Eric A Hughes |
BUY
Exercise of conversion of derivative security
|
Direct |
52,742
+50.0%
|
-
|
|
Jun 12
2025
|
Eliyahu Sharon Kalif EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
55,775
-12.15%
|
$948,175
$17.08 P/Share
|
|
Jun 06
2025
|
Janet S. Vergis |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+11.56%
|
-
|
|
Jun 06
2025
|
Varda Shalev |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+29.97%
|
-
|
|
Jun 06
2025
|
Tal Zvi Zaks |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+14.08%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 1.79M shares |
|---|---|
| Open market or private purchase | 1.11K shares |
| Open market or private sale | 2.09M shares |
|---|